A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus.

ABSTRACT:

Background

Flavivirus is a highly prevalent and outbreak-prone disease, affecting billions of individuals annually and posing substantial public health challenges. Vaccination is critical to reducing the global impact of flavivirus infections, making the development of a safe and effective vaccine a top priority. The self-assembled pan-epitope vaccine presents key advantages for improving immunogenicity and safety without relying on external vectors or adding immunomodulatory elements, both of which are essential for successful vaccine development.

Results

In this study, the pan-epitope peptide TBT was combined with adjuvant CpG to form the TBT-CpG nanovaccine (TBT-CpG NaVs), which was found to be spherical, uniform in shape, and demonstrated strong serum stability. In vitro

SUBMITTER: He J 

PROVIDER: S-EPMC11603839 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature